Maveropepimut-S: Our Lead Candidate To Tackle Hard-To-Treat Cancers

Maveropepimut-S (MVP-S, previously known as DPX-Survivac) is a T cell activating immunotherapy that combines the power of our propriety DPX Platform with cancer antigen survivin. Maveropepimut-S is the lead clinical candidate in IMV’s new class of immunotherapies that generates targeted T cells in vivo. By activating survivin-specific killer T cells, maveropepimut-S promotes the destruction of cancer cells and disrupts the fundamental processes of cancer cell production and survival.

View Maveropepimut-S (DPX-Survivac)